A promising hypertension risk prediction score using data from the United States Framingham Offspring study has been developed, but this score has not been tested in other cohorts. We examined the predictive performance of the Framingham hypertension risk score in a European population, the Whitehall II study. Participants were 6704 London-based civil servants aged 35 to 68, 31% women, free from prevalent hypertension, diabetes and coronary heart disease. Standard clinical examinations of blood pressure, weight and height, current cigarette smoking and parental history of hypertension were undertaken 5-yearly four times. We recorded a total of 2043 incident (new-onset) cases of hypertension in three 5-year baselinefollow-up data cycles. Both discrimination (C-statistic 0.80) and calibration (HosmerLemeshow chi-square 11.5) of the Framingham hypertension risk score were good.
INTRODUCTION
Hypertension, defined as systolic/diastolic blood pressure of >140/90 mm Hg, 1 is a risk factor for coronary heart disease, chronic heart failure, stroke, [1] [2] [3] [4] [5] [6] [7] chronic kidney disease, 8 premature mortality [1] [2] [3] and possibly also for dementia, in particular poststroke dementia. 9, 10 There is evidence to show that targeting high-risk but nonhypertensive individuals for treatment may delay hypertension onset. 11, 12 However, simple office-based tools to help clinicians identify high-risk people are lacking.
Recently, a promising risk prediction score using data from the U.S.
Framingham Offspring study has been developed. 13 First, it is simple, including only seven items: age, sex, systolic and diastolic blood pressure, body mass index, parental hypertension, and cigarette smoking (calculator available at www.annals.org). Second, the risk score was highly successful in estimating an individual's risk for hypertension for up to 4 years among participants in the Framingham study. These findings clearly warrant further testing beyond the cohort in which the risk score was developed. In this study, we examine the Framingham hypertension risk score in a large European population, the British Whitehall II study.
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The present analysis was based on 3 baseline-follow-up screening cycles (Table 1) . Participants were included if they attended two consecutive screenings between Phase 1 and Phase 7. At the baseline for each of the 3 screening cycles, we successively excluded those participants who had prevalent hypertension (n = 1472, 1196 and 1574 at Phases 1, 3 and 5, respectively), prevalent cardiovascular disease (n = 38, 86 and 155), prevalent diabetes (n = 48, 34 and 66), or missing data on risk factors (n = 491, 377 and 789). The baseline population at Phase 1 included 4620 men and 2084 women.
Ethical approval for the Whitehall II study was obtained from the University College London Medical School committee on the ethics of human research; all participants provided written informed consent.
Assessment of Risk Factors and Prevalent Disease
We measured systolic blood pressure and diastolic blood pressure twice in the sitting position after 5 minutes rest with the Hawksley random-zero sphygmomanometer (Phases 1 to 5) and OMRON HEM 907 (Phase 7). The average of the two readings was taken to be the measured systolic and diastolic blood pressure. Prehypertension was defined as systolic blood pressure from 120 to 139 mm Hg or diastolic blood pressure from 80 to 89 mm Hg. Current smoking and parental hypertension were self-reported. Weight was measured in underwear to the nearest 0.1 kg on Soehnle electronic scales. Height was measured in bare feet to the nearest 1 mm using a stadiometer with the participant standing erect with head in the Frankfort plane.
Body mass index (BMI) was calculated as weight (kilograms)/ height (meters) squared.
Prevalent coronary heart disease was defined by meeting MONICA criteria 
Assessment of Incident Hypertension
Hypertension was defined according to the 7th report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (systolic/diastolic>140/90 mm Hg or use of antihypertensive medication). 1 In each of the three screening cycles, we determined incident hypertension by presence of hypertension at follow-up among participants free of this condition at baseline (table 1) .
Statistical Analysis
Participants were followed across the screening cycles until incident hypertension or last study phase, whichever came first, contributing to a total of 13,679 personexaminations. The association between prehypertension at baseline and subsequent incident hypertension was summarised using odds ratios and 95% confidence intervals which were computed using standard methods. We examined the validity of the Framingham risk score in four steps. First, we examined whether prediction of incident hypertension based on prehypertension status improved following reclassification based on high Framingham risk score (corresponding to >20% predicted risk between successive screening cycles) using the net reclassification improvement (NRI). 18 We repeated this analysis with cut-offs >10% and >15% predicted risk to examine whether the findings were sensitive to the threshold used to define high risk using the Framingham risk score.
Second, we randomly split the person-examination observations into two groups, 60% for a 'derivation' dataset and 40% for a 'validation' dataset. We 6 developed a comparison risk prediction score based on the derivation data, using the same variables and statistical procedures as those used for the development of the Framingham hypertension risk score. 13 We identified significant predictors and interaction terms for incident hypertension in multivariable adjusted Weibull regression models for interval censored data.
Third, we calculated a risk prediction score ('the Whitehall II risk score') for the validation dataset from the β-coefficients obtained from the derivation cohort.
We calculated the Framingham risk score, using the β-coefficients derived in the Framingham study. 13 The variable parental hypertension included 2 categories (yes vs no) in the present study but 3 categories (neither parent, one parent, both parents) in the Framingham study. To produce a comparable β-coefficient that could be applied to the Whitehall data, we used the parental hypertension distribution presented in the Framingham paper to give a weighted average to the estimates from the per category increment coefficient. This resulted in a coefficient that shows the effect for the presence versus absence of parental hypertension. Both of the above scores were computed using the observed follow-up time for each participant within the follow-up cycle so that we could compare this predicted risk with the observed incident hypertension. With study examinations occurring every 5 years, results were expressed per 5 years.
Fourth, we assessed the performance of the risk prediction for both the Framingham and Whitehall II risk scores in the validation cohort. We compared the predicted hypertension incidence to the observed incidence for each decile category of both risk scores. We calculated the overall predicted-to-observed risk ratios for the whole validation cohort, separately by sex, age, risk factor groups and study cycle. We assessed discrimination based on C-statistics and calibration by using the modified Hosmer-Lemeshow chi-square statistics, again following the same procedures as the Framingham study. Table 2 presents characteristics of the 6704 participants. Their mean age at baseline was 44.6 years and 31% were women. Mean blood pressure was 118.9/ 74.6 mm Hg and 3646 (54.4%) were pre-hypertensive at baseline. Clinical features for the derivation and validation subcohorts were determined based on the 3 baseline examinations. As expected, the cohorts were very similar.
RESULTS

Baseline Characteristics
Prehypertension Risk Category vs Framingham Hypertension Risk Score
During the baseline-follow-up cycles (median length 5.6 years), we recorded a total of 2043 incident cases of hypertension (5-year hypertension incidence was 13. corresponding to >10% and >15% predicted risks resulted in net reclassification improvements of 4.5% (95% CI 2.1 -7.0%) and 8.5% (95% CI 5.6 -11.3%). These findings suggest that the superior prediction of incident hypertension with the Framingham hypertension risk score rather than prehypertension status was robust to various cut-off points to define high risk.
Developing a Comparison Score (the Whitehall II Risk Score)
To create a comparison risk score based on the Whitehall II data, we drew a 60% random sample from the total data. This derivation dataset included 8207 personexaminations. The Weibull β-coefficients for incident hypertension from a multivariable-adjusted model were used to calculate the Whitehall II hypertension risk score (table 3) . The hazard ratio for BMI was slightly greater (1.071 v 1.039) than that obtained in the Framingham study, 12 but differences in all other hazard ratios between the present study and the Framingham study were non-significant.
Comparison Between the Framingham and Whitehall II Risk Scores
The validation dataset was independent of the derivation data and comprised a total of 5472 person-examinations. The overall agreement between the predicted and observed incidence of hypertension was high across the risk score distribution for both the Framingham and Whitehall II risk scores (Figure 1) . The predicted-toobserved ratio for incident hypertension was close to one: 1.08 for both the On repeating this analysis with the highest risk groups split into a high risk (20-40%) group and a very high risk (>40%) group we found the net reclassification improvement was -1.0%, again showing that the Whitehall risk score did not result in a better prediction of incident hypertension than the Framingham hypertension risk score.
DISCUSSION
In a large cohort of non-hypertensive men and women aged 35 to 68, we showed that the Framingham hypertension risk score has high calibration and discrimination
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for predicting the risk of incident hypertension. The ratio of predicted-to-observed absolute risk of incident hypertension was close to 1 through the entire score distribution. Reclassification showed that the original Framingham risk score performs as well as the alternative Whitehall risk score derived here. These findings provide strong support for the validity of the Framingham hypertension risk score.
Clinical trials have demonstrated that treatment of prehypertensive individuals can prevent hypertension. 1, 11, 12, 19 However, prehypertension is highly prevalent and therefore treating all prehypertensive people would require substantial resources. 13 Our results show the Framingham hypertension risk score improves prediction of incident hypertension compared to that based on prehypertension status alone, and enabled a better identification of non-hypertensive individuals at the greatest risk. Superior prediction by the Framingham score is unsurprising given that it takes into account multiple independent risk factors. Furthermore, the algorithm treats blood pressure as a continuous variable rather than as a categorical one; this corresponds to the observation that the risk of cardiovascular disease increases in a continuous manner by increasing systolic and diastolic blood pressure levels above 115/75 mm Hg. 2 Studies evaluating a risk score on the same data on which the score was developed are prone to over-optimistic estimates of predictive performance. Our analysis shows that the results of the Framingham Offspring study which developed the hypertension risk score were highly replicable in an independent cohort and thus Offspring cohort. 13 No previous study has examined the predictive performance of the Framingham hypertension risk score by sex, age and in specific subgroups. We found the predicted-to-observed ratio was very similar in men and women, smokers and non-smokers, and participants with and without a history of parental hypertension.
The score slightly overestimated risk for normal weight people and those younger than 50. Thus, if the Framingham hypertension risk score was used, preventive treatment would be considered for these specific groups at a lower level of absolute hypertension risk than for the other groups.
Strengths and Limitations
The present study benefits from the large sample size, a design with multiple screening cycles, and the standardized protocols to assess risk factors. This study also has several limitations. First, the initial examination was in late 1980s when the prevalence of obesity was lower than at present. However, credibility that the Offspring study parents' blood pressure was measured. Direct measurement of parental hypertension is likely to provide more accurate information, but such data are seldom available. As the hypertension risk score will typically be determined based on self-reported parental hypertension in clinical practice, our measurement method is justified and strengthens ecological validity. Fourth, as our cohort comprised mostly white participants and did not include the unemployed, further validation studies are needed to confirm the generalisability of the findings in more heterogeneous populations.
Perspective
Risk models are used to target preventive treatments to individuals at the highest risk in order to facilitate cost effectiveness. Our investigation represents a crucial step in validating the simple office-based Framingham hypertension risk score which has not previously been tested beyond the cohort the scoring method was developed. Our study validated this risk score in a well-characterized British cohort that was larger than the original derivation dataset; we also demonstrated the predictive validity of the score separately among men and women and various risk 
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